newsfilter
← Latest News
GlobeNewswire·

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia

LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-